CLINICAL_TRIALS
trial_result
· 2022-01-14
Clinical Trial Update: Study of Nivolumab in Unresectable Advanced or Recurrent Esophageal Cancer [Phase 3]
Summary
A Phase 3 trial assessing nivolumab in unresectable advanced or recurrent esophageal cancer has completed with results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Ono Pharmaceutical Co., Ltd. | Conditions: Esophageal Cancer | Phase 3 | Status: COMPLETED | Results posted: 2022-01-14